Heidelberg Pharma AG
Clinical-stage biopharma developing Amanitin-based ADCs for targeted cancer therapies.
HPHA | F
Overview
Corporate Details
- ISIN(s):
- DE000A11QVV0
- LEI:
- 391200E09XYBYITR1W32
- Country:
- Germany
- Address:
- Gregor-Mendel-Str. 22, 68526 Ladenburg
- Sector:
- Manufacturing
Description
Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-08-08 07:46 |
Heidelberg Pharma AG: Heidelberg Pharmas Partner Takeda Reached Development Mil…
|
English | 10.2 KB | ||
| 2023-07-13 07:04 |
Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business
|
English | 32.0 KB | ||
| 2023-07-13 00:00 |
Halbjahresfinanzbericht nach WpHG für den Zeitraum vom 01.12.2022 bis zum 31.05…
|
German | 145.9 KB | ||
| 2023-07-13 00:00 |
Half-yearly financial report 2022/2023
|
German | 954.3 KB | ||
| 2023-06-30 17:30 |
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
|
English | 4.5 KB | ||
| 2023-06-29 09:45 |
Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics
|
English | 9.5 KB | ||
| 2023-05-31 17:30 |
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
|
English | 4.5 KB | ||
| 2023-05-26 16:04 |
Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, buy
|
English | 7.7 KB | ||
| 2023-05-25 15:17 |
Heidelberg Pharma reports on the results of the Annual General Meeting 2023
|
English | 9.5 KB | ||
| 2023-05-05 12:25 |
Heidelberg Pharma appoints Chief Financial Officer
|
English | 10.6 KB | ||
| 2023-04-28 18:14 |
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
|
English | 4.5 KB | ||
| 2023-04-19 00:00 |
Q1 statement / Q1 financial report 2022/2023
|
English | 188.8 KB | ||
| 2023-04-13 15:05 |
Heidelberg Pharma AG: Bekanntmachung der Einberufung zur Hauptversammlung am 25…
|
German | 247.4 KB | ||
| 2023-04-13 07:10 |
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of…
|
English | 28.3 KB | ||
| 2023-04-04 10:12 |
Heidelberg Pharma Presents New Preclinical Data from its Proprietary ATAC Techn…
|
English | 15.2 KB |
Automate Your Workflow. Get a real-time feed of all Heidelberg Pharma AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Heidelberg Pharma AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Heidelberg Pharma AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-31 | Pahl, Prof. Dr. Andreas | Board | Other | None | N/A |
| 2023-12-18 | Pahl, Prof. Dr. Andreas | Board | Buy | None | 10,130.00 EUR |
| 2022-10-13 | 4H invest GmbH | Close relation | Other | None | 993,666.24 EUR |
| 2022-10-13 | Bohlini invest GmbH | Close relation | Other | None | 964,061.56 EUR |
| 2022-10-13 | MH-LT-Investments GmbH | Close relation | Other | None | 506,241.96 EUR |
| 2022-10-13 | Schneiders, Michael | Board | Buy | None | 13,088.40 EUR |
| 2022-10-13 | Schneiders, Michael | Board | Buy | None | 4,895.60 EUR |
| 2022-09-07 | Plate, Achim | Board | Buy | None | 30,869.92 EUR |
| 2022-09-06 | Kudlek, Dr. Birgit | Supervisory board | Other | None | 7,496.16 EUR |
| 2022-03-22 | 4H invest GmbH | Close relation | Other | None | N/A |
Peer Companies
